nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—EPHX2—Fulvestrant—breast cancer	0.143	0.453	CbGbCtD
Regorafenib—RAF1—breast cancer	0.0589	0.142	CbGaD
Regorafenib—FGFR1—breast cancer	0.0579	0.14	CbGaD
Regorafenib—FGFR2—breast cancer	0.0579	0.14	CbGaD
Regorafenib—FLT1—breast cancer	0.0554	0.134	CbGaD
Regorafenib—BRAF—breast cancer	0.0408	0.0986	CbGaD
Regorafenib—ABL1—breast cancer	0.0408	0.0986	CbGaD
Regorafenib—KDR—breast cancer	0.0347	0.0838	CbGaD
Regorafenib—KIT—breast cancer	0.0328	0.0791	CbGaD
Regorafenib—ABCG2—breast cancer	0.0181	0.0438	CbGaD
Regorafenib—UGT1A9—Irinotecan—breast cancer	0.00912	0.0288	CbGbCtD
Regorafenib—CYP3A4—breast cancer	0.00907	0.0219	CbGaD
Regorafenib—CYP2B6—Thiotepa—breast cancer	0.00852	0.0269	CbGbCtD
Regorafenib—ABCB1—breast cancer	0.00755	0.0182	CbGaD
Regorafenib—UGT1A1—Irinotecan—breast cancer	0.00746	0.0236	CbGbCtD
Regorafenib—CYP2C9—Anastrozole—breast cancer	0.00594	0.0188	CbGbCtD
Regorafenib—CYP2B6—Raloxifene—breast cancer	0.00568	0.018	CbGbCtD
Regorafenib—CYP2C8—Lapatinib—breast cancer	0.00568	0.0179	CbGbCtD
Regorafenib—ABCG2—Tamoxifen—breast cancer	0.00534	0.0169	CbGbCtD
Regorafenib—ABCB1—Toremifene—breast cancer	0.00527	0.0167	CbGbCtD
Regorafenib—ABCG2—Mitoxantrone—breast cancer	0.00521	0.0165	CbGbCtD
Regorafenib—CYP2C19—Lapatinib—breast cancer	0.00477	0.0151	CbGbCtD
Regorafenib—CYP3A4—Exemestane—breast cancer	0.00456	0.0144	CbGbCtD
Regorafenib—CYP2C9—Idarubicin—breast cancer	0.0045	0.0142	CbGbCtD
Regorafenib—CYP2C8—Raloxifene—breast cancer	0.00431	0.0136	CbGbCtD
Regorafenib—ABCG2—Paclitaxel—breast cancer	0.00416	0.0131	CbGbCtD
Regorafenib—ABCG2—Irinotecan—breast cancer	0.0041	0.013	CbGbCtD
Regorafenib—ABCG2—Fluorouracil—breast cancer	0.00394	0.0124	CbGbCtD
Regorafenib—ABCG2—Carboplatin—breast cancer	0.00391	0.0124	CbGbCtD
Regorafenib—CYP3A4—Letrozole—breast cancer	0.00387	0.0122	CbGbCtD
Regorafenib—ABCB1—Lapatinib—breast cancer	0.00385	0.0121	CbGbCtD
Regorafenib—CYP2B6—Tamoxifen—breast cancer	0.00376	0.0119	CbGbCtD
Regorafenib—CYP3A4—Anastrozole—breast cancer	0.00345	0.0109	CbGbCtD
Regorafenib—CYP3A4—Toremifene—breast cancer	0.00316	0.00998	CbGbCtD
Regorafenib—ABCG2—Docetaxel—breast cancer	0.00301	0.00949	CbGbCtD
Regorafenib—CYP3A4—Fulvestrant—breast cancer	0.00294	0.00928	CbGbCtD
Regorafenib—CYP2B6—Irinotecan—breast cancer	0.00288	0.00911	CbGbCtD
Regorafenib—CYP2C8—Tamoxifen—breast cancer	0.00284	0.00899	CbGbCtD
Regorafenib—CYP3A4—Thiotepa—breast cancer	0.00262	0.00827	CbGbCtD
Regorafenib—CYP2C9—Capecitabine—breast cancer	0.00247	0.00779	CbGbCtD
Regorafenib—CYP3A4—Ixabepilone—breast cancer	0.00239	0.00756	CbGbCtD
Regorafenib—CYP2C19—Tamoxifen—breast cancer	0.00239	0.00754	CbGbCtD
Regorafenib—CYP3A4—Lapatinib—breast cancer	0.0023	0.00728	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—breast cancer	0.00224	0.00708	CbGbCtD
Regorafenib—CYP2C8—Paclitaxel—breast cancer	0.00221	0.007	CbGbCtD
Regorafenib—ABCG2—Methotrexate—breast cancer	0.00217	0.00686	CbGbCtD
Regorafenib—ABCB1—Vinorelbine—breast cancer	0.00213	0.00674	CbGbCtD
Regorafenib—CYP2C8—Fluorouracil—breast cancer	0.0021	0.00662	CbGbCtD
Regorafenib—CYP2C9—Tamoxifen—breast cancer	0.00198	0.00627	CbGbCtD
Regorafenib—ABCB1—Tamoxifen—breast cancer	0.00193	0.00608	CbGbCtD
Regorafenib—ABCB1—Mitoxantrone—breast cancer	0.00188	0.00593	CbGbCtD
Regorafenib—CYP3A4—Raloxifene—breast cancer	0.00175	0.00552	CbGbCtD
Regorafenib—ABCB1—Gemcitabine—breast cancer	0.00166	0.00524	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—breast cancer	0.00158	0.00498	CbGbCtD
Regorafenib—CYP2C9—Paclitaxel—breast cancer	0.00154	0.00488	CbGbCtD
Regorafenib—ABCB1—Paclitaxel—breast cancer	0.0015	0.00474	CbGbCtD
Regorafenib—ABCB1—Irinotecan—breast cancer	0.00148	0.00467	CbGbCtD
Regorafenib—CYP2C9—Fluorouracil—breast cancer	0.00146	0.00462	CbGbCtD
Regorafenib—ABCB1—Vinblastine—breast cancer	0.00131	0.00415	CbGbCtD
Regorafenib—FLT1—umbilical vein—breast cancer	0.0013	0.0244	CbGeAlD
Regorafenib—CYP3A4—Vinorelbine—breast cancer	0.00128	0.00404	CbGbCtD
Regorafenib—CYP3A4—Tamoxifen—breast cancer	0.00115	0.00365	CbGbCtD
Regorafenib—CYP3A4—Mitoxantrone—breast cancer	0.00113	0.00356	CbGbCtD
Regorafenib—KDR—umbilical vein—breast cancer	0.0011	0.0206	CbGeAlD
Regorafenib—ABCB1—Docetaxel—breast cancer	0.00108	0.00342	CbGbCtD
Regorafenib—DDR2—mammary gland—breast cancer	0.00105	0.0197	CbGeAlD
Regorafenib—MAPK11—mammary gland—breast cancer	0.000996	0.0187	CbGeAlD
Regorafenib—CYP3A4—Paclitaxel—breast cancer	0.000898	0.00284	CbGbCtD
Regorafenib—CYP3A4—Irinotecan—breast cancer	0.000886	0.0028	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—breast cancer	0.000808	0.00255	CbGbCtD
Regorafenib—CYP3A4—Vinblastine—breast cancer	0.000788	0.00249	CbGbCtD
Regorafenib—ABCB1—Methotrexate—breast cancer	0.000782	0.00247	CbGbCtD
Regorafenib—EPHX2—mammary gland—breast cancer	0.000709	0.0133	CbGeAlD
Regorafenib—CYP3A4—Docetaxel—breast cancer	0.000649	0.00205	CbGbCtD
Regorafenib—FGFR2—Estradiol—Fulvestrant—breast cancer	0.000603	0.301	CbGdCrCtD
Regorafenib—RET—mammary gland—breast cancer	0.000565	0.0106	CbGeAlD
Regorafenib—DDR2—skin of body—breast cancer	0.000556	0.0104	CbGeAlD
Regorafenib—FGFR2—mammary gland—breast cancer	0.000537	0.0101	CbGeAlD
Regorafenib—RAF1—Topotecan—Irinotecan—breast cancer	0.000534	0.267	CbGdCrCtD
Regorafenib—EPHA2—mammary gland—breast cancer	0.000527	0.00989	CbGeAlD
Regorafenib—DDR2—endometrium—breast cancer	0.000524	0.00983	CbGeAlD
Regorafenib—TEK—mammary gland—breast cancer	0.000514	0.00965	CbGeAlD
Regorafenib—Sorafenib—RAF1—breast cancer	0.000498	0.156	CrCbGaD
Regorafenib—Sorafenib—FGFR1—breast cancer	0.00049	0.153	CrCbGaD
Regorafenib—FRK—female reproductive system—breast cancer	0.000484	0.00908	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—breast cancer	0.000484	0.00153	CbGbCtD
Regorafenib—DDR2—uterus—breast cancer	0.000483	0.00906	CbGeAlD
Regorafenib—DDR2—pituitary gland—breast cancer	0.000475	0.0089	CbGeAlD
Regorafenib—DDR2—adipose tissue—breast cancer	0.000473	0.00886	CbGeAlD
Regorafenib—Sorafenib—FLT1—breast cancer	0.000469	0.146	CrCbGaD
Regorafenib—PDGFRA—mammary gland—breast cancer	0.000466	0.00874	CbGeAlD
Regorafenib—MAPK11—adipose tissue—breast cancer	0.000448	0.0084	CbGeAlD
Regorafenib—Sorafenib—CSF1R—breast cancer	0.000444	0.139	CrCbGaD
Regorafenib—FLT4—embryo—breast cancer	0.000437	0.00819	CbGeAlD
Regorafenib—EPHA2—nipple—breast cancer	0.000436	0.00818	CbGeAlD
Regorafenib—DDR2—female reproductive system—breast cancer	0.000434	0.00815	CbGeAlD
Regorafenib—DDR2—adrenal gland—breast cancer	0.000424	0.00795	CbGeAlD
Regorafenib—KDR—mammary gland—breast cancer	0.00042	0.00788	CbGeAlD
Regorafenib—MAPK11—female reproductive system—breast cancer	0.000412	0.00772	CbGeAlD
Regorafenib—FLT1—nipple—breast cancer	0.000411	0.00771	CbGeAlD
Regorafenib—FRK—endocrine gland—breast cancer	0.00041	0.00769	CbGeAlD
Regorafenib—RAF1—nipple—breast cancer	0.000409	0.00767	CbGeAlD
Regorafenib—MAPK11—adrenal gland—breast cancer	0.000402	0.00754	CbGeAlD
Regorafenib—DDR2—female gonad—breast cancer	0.000395	0.00741	CbGeAlD
Regorafenib—RET—embryo—breast cancer	0.000385	0.00723	CbGeAlD
Regorafenib—MAPK11—female gonad—breast cancer	0.000375	0.00703	CbGeAlD
Regorafenib—KIT—mammary gland—breast cancer	0.000373	0.00699	CbGeAlD
Regorafenib—BRAF—endometrium—breast cancer	0.000371	0.00695	CbGeAlD
Regorafenib—DDR2—endocrine gland—breast cancer	0.000368	0.00689	CbGeAlD
Regorafenib—FGFR2—embryo—breast cancer	0.000366	0.00687	CbGeAlD
Regorafenib—PDGFRB—mammary gland—breast cancer	0.000364	0.00682	CbGeAlD
Regorafenib—FLT4—epithelium—breast cancer	0.000356	0.00668	CbGeAlD
Regorafenib—TEK—embryo—breast cancer	0.000351	0.00658	CbGeAlD
Regorafenib—KDR—nipple—breast cancer	0.000348	0.00652	CbGeAlD
Regorafenib—Sorafenib—BRAF—breast cancer	0.000345	0.108	CrCbGaD
Regorafenib—BRAF—uterus—breast cancer	0.000342	0.00641	CbGeAlD
Regorafenib—FLT1—embryo—breast cancer	0.000339	0.00637	CbGeAlD
Regorafenib—RAF1—embryo—breast cancer	0.000338	0.00633	CbGeAlD
Regorafenib—BRAF—pituitary gland—breast cancer	0.000335	0.00629	CbGeAlD
Regorafenib—BRAF—adipose tissue—breast cancer	0.000334	0.00626	CbGeAlD
Regorafenib—EPHX2—uterus—breast cancer	0.000326	0.00612	CbGeAlD
Regorafenib—ABL1—mammary gland—breast cancer	0.000324	0.00608	CbGeAlD
Regorafenib—EPHX2—pituitary gland—breast cancer	0.000321	0.00601	CbGeAlD
Regorafenib—EPHX2—adipose tissue—breast cancer	0.000319	0.00599	CbGeAlD
Regorafenib—PDGFRA—embryo—breast cancer	0.000318	0.00596	CbGeAlD
Regorafenib—RET—epithelium—breast cancer	0.000315	0.0059	CbGeAlD
Regorafenib—KIT—nipple—breast cancer	0.000308	0.00578	CbGeAlD
Regorafenib—PDGFRB—nipple—breast cancer	0.000301	0.00564	CbGeAlD
Regorafenib—BRAF—adrenal gland—breast cancer	0.0003	0.00562	CbGeAlD
Regorafenib—FGFR2—epithelium—breast cancer	0.000299	0.0056	CbGeAlD
Regorafenib—Sorafenib—KDR—breast cancer	0.000294	0.0918	CrCbGaD
Regorafenib—EPHA2—epithelium—breast cancer	0.000294	0.00551	CbGeAlD
Regorafenib—FGFR1—uterus—breast cancer	0.00029	0.00545	CbGeAlD
Regorafenib—BRAF—bone marrow—breast cancer	0.00029	0.00544	CbGeAlD
Regorafenib—FLT4—adipose tissue—breast cancer	0.000288	0.0054	CbGeAlD
Regorafenib—KDR—embryo—breast cancer	0.000287	0.00538	CbGeAlD
Regorafenib—TEK—epithelium—breast cancer	0.000287	0.00537	CbGeAlD
Regorafenib—EPHX2—adrenal gland—breast cancer	0.000286	0.00537	CbGeAlD
Regorafenib—FGFR1—pituitary gland—breast cancer	0.000285	0.00535	CbGeAlD
Regorafenib—FGFR2—skin of body—breast cancer	0.000284	0.00533	CbGeAlD
Regorafenib—FGFR1—adipose tissue—breast cancer	0.000284	0.00533	CbGeAlD
Regorafenib—BRAF—female gonad—breast cancer	0.000279	0.00524	CbGeAlD
Regorafenib—Sorafenib—KIT—breast cancer	0.000277	0.0866	CrCbGaD
Regorafenib—FLT1—epithelium—breast cancer	0.000277	0.00519	CbGeAlD
Regorafenib—RAF1—epithelium—breast cancer	0.000275	0.00516	CbGeAlD
Regorafenib—ABL1—nipple—breast cancer	0.000268	0.00503	CbGeAlD
Regorafenib—EPHX2—female gonad—breast cancer	0.000267	0.00501	CbGeAlD
Regorafenib—FLT4—female reproductive system—breast cancer	0.000265	0.00496	CbGeAlD
Regorafenib—EPHA2—endometrium—breast cancer	0.000263	0.00494	CbGeAlD
Regorafenib—RAF1—skin of body—breast cancer	0.000262	0.00491	CbGeAlD
Regorafenib—FLT4—adrenal gland—breast cancer	0.000258	0.00484	CbGeAlD
Regorafenib—TEK—endometrium—breast cancer	0.000257	0.00482	CbGeAlD
Regorafenib—RET—pituitary gland—breast cancer	0.000255	0.00479	CbGeAlD
Regorafenib—FGFR1—adrenal gland—breast cancer	0.000255	0.00478	CbGeAlD
Regorafenib—KIT—embryo—breast cancer	0.000254	0.00477	CbGeAlD
Regorafenib—DDR2—lymph node—breast cancer	0.000254	0.00477	CbGeAlD
Regorafenib—FLT4—bone marrow—breast cancer	0.00025	0.00469	CbGeAlD
Regorafenib—FLT1—endometrium—breast cancer	0.000248	0.00466	CbGeAlD
Regorafenib—PDGFRB—embryo—breast cancer	0.000248	0.00466	CbGeAlD
Regorafenib—RAF1—endometrium—breast cancer	0.000247	0.00463	CbGeAlD
Regorafenib—FGFR2—uterus—breast cancer	0.000247	0.00463	CbGeAlD
Regorafenib—FGFR2—adipose tissue—breast cancer	0.000242	0.00453	CbGeAlD
Regorafenib—MAPK11—lymph node—breast cancer	0.000241	0.00452	CbGeAlD
Regorafenib—FLT4—female gonad—breast cancer	0.000241	0.00452	CbGeAlD
Regorafenib—EPHA2—pituitary gland—breast cancer	0.000238	0.00447	CbGeAlD
Regorafenib—FGFR1—female gonad—breast cancer	0.000238	0.00445	CbGeAlD
Regorafenib—EPHA2—adipose tissue—breast cancer	0.000237	0.00445	CbGeAlD
Regorafenib—TEK—uterus—breast cancer	0.000237	0.00444	CbGeAlD
Regorafenib—KDR—epithelium—breast cancer	0.000234	0.00439	CbGeAlD
Regorafenib—TEK—pituitary gland—breast cancer	0.000233	0.00436	CbGeAlD
Regorafenib—TEK—adipose tissue—breast cancer	0.000232	0.00434	CbGeAlD
Regorafenib—FLT1—uterus—breast cancer	0.000229	0.00429	CbGeAlD
Regorafenib—RET—adrenal gland—breast cancer	0.000228	0.00428	CbGeAlD
Regorafenib—RAF1—uterus—breast cancer	0.000228	0.00427	CbGeAlD
Regorafenib—UGT1A9—endocrine gland—breast cancer	0.000227	0.00426	CbGeAlD
Regorafenib—FLT1—pituitary gland—breast cancer	0.000225	0.00422	CbGeAlD
Regorafenib—FLT4—endocrine gland—breast cancer	0.000224	0.0042	CbGeAlD
Regorafenib—FLT1—adipose tissue—breast cancer	0.000224	0.0042	CbGeAlD
Regorafenib—RAF1—pituitary gland—breast cancer	0.000223	0.00419	CbGeAlD
Regorafenib—RAF1—adipose tissue—breast cancer	0.000223	0.00417	CbGeAlD
Regorafenib—FGFR2—female reproductive system—breast cancer	0.000222	0.00416	CbGeAlD
Regorafenib—ABL1—Topotecan—Irinotecan—breast cancer	0.000222	0.111	CbGdCrCtD
Regorafenib—ABL1—embryo—breast cancer	0.000221	0.00415	CbGeAlD
Regorafenib—EPHA2—female reproductive system—breast cancer	0.000218	0.00409	CbGeAlD
Regorafenib—FGFR2—adrenal gland—breast cancer	0.000217	0.00406	CbGeAlD
Regorafenib—PDGFRA—uterus—breast cancer	0.000215	0.00402	CbGeAlD
Regorafenib—EPHA2—adrenal gland—breast cancer	0.000213	0.00399	CbGeAlD
Regorafenib—TEK—female reproductive system—breast cancer	0.000213	0.00399	CbGeAlD
Regorafenib—CYP2C8—mammary gland—breast cancer	0.00021	0.00394	CbGeAlD
Regorafenib—KDR—endometrium—breast cancer	0.00021	0.00394	CbGeAlD
Regorafenib—PDGFRA—adipose tissue—breast cancer	0.00021	0.00393	CbGeAlD
Regorafenib—TEK—adrenal gland—breast cancer	0.000208	0.00389	CbGeAlD
Regorafenib—KIT—epithelium—breast cancer	0.000208	0.00389	CbGeAlD
Regorafenib—FLT1—female reproductive system—breast cancer	0.000206	0.00386	CbGeAlD
Regorafenib—RAF1—female reproductive system—breast cancer	0.000205	0.00384	CbGeAlD
Regorafenib—PDGFRB—epithelium—breast cancer	0.000203	0.0038	CbGeAlD
Regorafenib—FGFR2—female gonad—breast cancer	0.000202	0.00379	CbGeAlD
Regorafenib—FLT1—adrenal gland—breast cancer	0.000201	0.00377	CbGeAlD
Regorafenib—RAF1—adrenal gland—breast cancer	0.0002	0.00374	CbGeAlD
Regorafenib—EPHA2—female gonad—breast cancer	0.000199	0.00372	CbGeAlD
Regorafenib—RET—endocrine gland—breast cancer	0.000198	0.00371	CbGeAlD
Regorafenib—KIT—skin of body—breast cancer	0.000197	0.0037	CbGeAlD
Regorafenib—TEK—female gonad—breast cancer	0.000194	0.00363	CbGeAlD
Regorafenib—KDR—uterus—breast cancer	0.000194	0.00363	CbGeAlD
Regorafenib—RAF1—bone marrow—breast cancer	0.000193	0.00362	CbGeAlD
Regorafenib—PDGFRA—female reproductive system—breast cancer	0.000193	0.00362	CbGeAlD
Regorafenib—PDGFRB—skin of body—breast cancer	0.000193	0.00361	CbGeAlD
Regorafenib—KDR—pituitary gland—breast cancer	0.00019	0.00356	CbGeAlD
Regorafenib—KDR—adipose tissue—breast cancer	0.000189	0.00355	CbGeAlD
Regorafenib—PDGFRA—adrenal gland—breast cancer	0.000188	0.00353	CbGeAlD
Regorafenib—FGFR2—endocrine gland—breast cancer	0.000188	0.00352	CbGeAlD
Regorafenib—FLT1—female gonad—breast cancer	0.000187	0.00351	CbGeAlD
Regorafenib—CYP2C9—mammary gland—breast cancer	0.000187	0.0035	CbGeAlD
Regorafenib—RAF1—female gonad—breast cancer	0.000186	0.00349	CbGeAlD
Regorafenib—KIT—endometrium—breast cancer	0.000186	0.00349	CbGeAlD
Regorafenib—EPHA2—endocrine gland—breast cancer	0.000185	0.00346	CbGeAlD
Regorafenib—PDGFRB—endometrium—breast cancer	0.000182	0.00341	CbGeAlD
Regorafenib—TEK—endocrine gland—breast cancer	0.00018	0.00338	CbGeAlD
Regorafenib—BRAF—lymph node—breast cancer	0.00018	0.00337	CbGeAlD
Regorafenib—PDGFRA—female gonad—breast cancer	0.000175	0.00329	CbGeAlD
Regorafenib—FLT1—endocrine gland—breast cancer	0.000174	0.00327	CbGeAlD
Regorafenib—KDR—female reproductive system—breast cancer	0.000174	0.00326	CbGeAlD
Regorafenib—RAF1—endocrine gland—breast cancer	0.000173	0.00325	CbGeAlD
Regorafenib—ABL1—skin of body—breast cancer	0.000172	0.00322	CbGeAlD
Regorafenib—EPHX2—lymph node—breast cancer	0.000172	0.00322	CbGeAlD
Regorafenib—KIT—uterus—breast cancer	0.000171	0.00322	CbGeAlD
Regorafenib—KDR—adrenal gland—breast cancer	0.00017	0.00318	CbGeAlD
Regorafenib—KIT—pituitary gland—breast cancer	0.000168	0.00316	CbGeAlD
Regorafenib—KIT—adipose tissue—breast cancer	0.000168	0.00314	CbGeAlD
Regorafenib—PDGFRB—uterus—breast cancer	0.000167	0.00314	CbGeAlD
Regorafenib—PDGFRB—pituitary gland—breast cancer	0.000164	0.00308	CbGeAlD
Regorafenib—KDR—bone marrow—breast cancer	0.000164	0.00308	CbGeAlD
Regorafenib—PDGFRB—adipose tissue—breast cancer	0.000164	0.00307	CbGeAlD
Regorafenib—PDGFRA—endocrine gland—breast cancer	0.000163	0.00306	CbGeAlD
Regorafenib—ABL1—endometrium—breast cancer	0.000162	0.00304	CbGeAlD
Regorafenib—KDR—female gonad—breast cancer	0.000158	0.00297	CbGeAlD
Regorafenib—UGT1A1—endocrine gland—breast cancer	0.000156	0.00292	CbGeAlD
Regorafenib—FLT4—lymph node—breast cancer	0.000155	0.0029	CbGeAlD
Regorafenib—KIT—female reproductive system—breast cancer	0.000154	0.00289	CbGeAlD
Regorafenib—Sorafenib—ABCG2—breast cancer	0.000153	0.048	CrCbGaD
Regorafenib—FGFR1—lymph node—breast cancer	0.000153	0.00286	CbGeAlD
Regorafenib—PDGFRB—female reproductive system—breast cancer	0.000151	0.00282	CbGeAlD
Regorafenib—KIT—adrenal gland—breast cancer	0.00015	0.00282	CbGeAlD
Regorafenib—ABL1—uterus—breast cancer	0.000149	0.0028	CbGeAlD
Regorafenib—KDR—endocrine gland—breast cancer	0.000147	0.00276	CbGeAlD
Regorafenib—PDGFRB—adrenal gland—breast cancer	0.000147	0.00276	CbGeAlD
Regorafenib—ABL1—pituitary gland—breast cancer	0.000147	0.00275	CbGeAlD
Regorafenib—ABL1—adipose tissue—breast cancer	0.000146	0.00274	CbGeAlD
Regorafenib—KIT—bone marrow—breast cancer	0.000146	0.00273	CbGeAlD
Regorafenib—PDGFRB—bone marrow—breast cancer	0.000142	0.00267	CbGeAlD
Regorafenib—KIT—female gonad—breast cancer	0.00014	0.00263	CbGeAlD
Regorafenib—PDGFRB—female gonad—breast cancer	0.000137	0.00257	CbGeAlD
Regorafenib—RET—lymph node—breast cancer	0.000137	0.00256	CbGeAlD
Regorafenib—ABL1—female reproductive system—breast cancer	0.000134	0.00252	CbGeAlD
Regorafenib—ABL1—adrenal gland—breast cancer	0.000131	0.00246	CbGeAlD
Regorafenib—KIT—endocrine gland—breast cancer	0.00013	0.00245	CbGeAlD
Regorafenib—EPHA2—lymph node—breast cancer	0.000128	0.00239	CbGeAlD
Regorafenib—PDGFRB—endocrine gland—breast cancer	0.000127	0.00239	CbGeAlD
Regorafenib—ABL1—bone marrow—breast cancer	0.000127	0.00238	CbGeAlD
Regorafenib—TEK—lymph node—breast cancer	0.000125	0.00233	CbGeAlD
Regorafenib—ABL1—female gonad—breast cancer	0.000122	0.00229	CbGeAlD
Regorafenib—FLT1—lymph node—breast cancer	0.00012	0.00226	CbGeAlD
Regorafenib—RAF1—lymph node—breast cancer	0.00012	0.00224	CbGeAlD
Regorafenib—ABL1—endocrine gland—breast cancer	0.000114	0.00213	CbGeAlD
Regorafenib—ABL1—Epirubicin—Idarubicin—breast cancer	0.000113	0.0567	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Idarubicin—breast cancer	0.000113	0.0567	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Idarubicin—breast cancer	0.000113	0.0567	CbGdCrCtD
Regorafenib—PDGFRA—lymph node—breast cancer	0.000113	0.00212	CbGeAlD
Regorafenib—CYP2C8—endometrium—breast cancer	0.000105	0.00197	CbGeAlD
Regorafenib—ABCG2—endometrium—breast cancer	0.000102	0.00192	CbGeAlD
Regorafenib—KDR—lymph node—breast cancer	0.000102	0.00191	CbGeAlD
Regorafenib—CYP2B6—skin of body—breast cancer	0.0001	0.00187	CbGeAlD
Regorafenib—CYP2C8—pituitary gland—breast cancer	9.51e-05	0.00178	CbGeAlD
Regorafenib—ABCG2—uterus—breast cancer	9.41e-05	0.00177	CbGeAlD
Regorafenib—ABCG2—pituitary gland—breast cancer	9.24e-05	0.00173	CbGeAlD
Regorafenib—ABCG2—adipose tissue—breast cancer	9.21e-05	0.00173	CbGeAlD
Regorafenib—KIT—lymph node—breast cancer	9.02e-05	0.00169	CbGeAlD
Regorafenib—Sorafenib—CYP2D6—breast cancer	8.95e-05	0.028	CrCbGaD
Regorafenib—PDGFRB—lymph node—breast cancer	8.81e-05	0.00165	CbGeAlD
Regorafenib—CYP2C8—female reproductive system—breast cancer	8.7e-05	0.00163	CbGeAlD
Regorafenib—CYP2C19—endocrine gland—breast cancer	8.44e-05	0.00158	CbGeAlD
Regorafenib—ABCG2—adrenal gland—breast cancer	8.26e-05	0.00155	CbGeAlD
Regorafenib—ABCG2—bone marrow—breast cancer	7.99e-05	0.0015	CbGeAlD
Regorafenib—ABL1—lymph node—breast cancer	7.85e-05	0.00147	CbGeAlD
Regorafenib—CYP2B6—female reproductive system—breast cancer	7.81e-05	0.00146	CbGeAlD
Regorafenib—CYP2C9—female reproductive system—breast cancer	7.73e-05	0.00145	CbGeAlD
Regorafenib—ABCG2—female gonad—breast cancer	7.7e-05	0.00144	CbGeAlD
Regorafenib—Sorafenib—CYP3A4—breast cancer	7.67e-05	0.024	CrCbGaD
Regorafenib—CYP2B6—adrenal gland—breast cancer	7.62e-05	0.00143	CbGeAlD
Regorafenib—CYP2C8—endocrine gland—breast cancer	7.37e-05	0.00138	CbGeAlD
Regorafenib—ABCB1—embryo—breast cancer	6.88e-05	0.00129	CbGeAlD
Regorafenib—CYP2B6—endocrine gland—breast cancer	6.61e-05	0.00124	CbGeAlD
Regorafenib—CYP2C9—endocrine gland—breast cancer	6.54e-05	0.00123	CbGeAlD
Regorafenib—Sorafenib—ABCB1—breast cancer	6.39e-05	0.02	CrCbGaD
Regorafenib—CYP3A4—female reproductive system—breast cancer	5.9e-05	0.00111	CbGeAlD
Regorafenib—ABCB1—epithelium—breast cancer	5.62e-05	0.00105	CbGeAlD
Regorafenib—ABL1—Doxorubicin—Epirubicin—breast cancer	5.21e-05	0.0261	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—breast cancer	5.21e-05	0.0261	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—breast cancer	5.21e-05	0.0261	CbGdCrCtD
Regorafenib—ABCB1—endometrium—breast cancer	5.04e-05	0.000945	CbGeAlD
Regorafenib—CYP3A4—endocrine gland—breast cancer	4.99e-05	0.000935	CbGeAlD
Regorafenib—ABCG2—lymph node—breast cancer	4.95e-05	0.000928	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—breast cancer	4.82e-05	0.0241	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—breast cancer	4.82e-05	0.0241	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—breast cancer	4.82e-05	0.0241	CbGdCrCtD
Regorafenib—ABCB1—uterus—breast cancer	4.64e-05	0.00087	CbGeAlD
Regorafenib—ABCB1—pituitary gland—breast cancer	4.56e-05	0.000855	CbGeAlD
Regorafenib—ABCB1—adipose tissue—breast cancer	4.54e-05	0.000851	CbGeAlD
Regorafenib—ABCB1—female reproductive system—breast cancer	4.17e-05	0.000782	CbGeAlD
Regorafenib—ABCB1—adrenal gland—breast cancer	4.07e-05	0.000764	CbGeAlD
Regorafenib—ABCB1—bone marrow—breast cancer	3.94e-05	0.000739	CbGeAlD
Regorafenib—ABCB1—female gonad—breast cancer	3.8e-05	0.000712	CbGeAlD
Regorafenib—Nausea—Tamoxifen—breast cancer	3.74e-05	0.000394	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Gemcitabine—breast cancer	3.74e-05	0.000393	CcSEcCtD
Regorafenib—Fatigue—Gemcitabine—breast cancer	3.73e-05	0.000393	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—breast cancer	3.72e-05	0.000391	CcSEcCtD
Regorafenib—Pain—Gemcitabine—breast cancer	3.7e-05	0.00039	CcSEcCtD
Regorafenib—Decreased appetite—Fluorouracil—breast cancer	3.7e-05	0.00039	CcSEcCtD
Regorafenib—Alopecia—Capecitabine—breast cancer	3.7e-05	0.000389	CcSEcCtD
Regorafenib—Dry mouth—Paclitaxel—breast cancer	3.7e-05	0.000389	CcSEcCtD
Regorafenib—Asthenia—Thiotepa—breast cancer	3.69e-05	0.000389	CcSEcCtD
Regorafenib—Diarrhoea—Vinorelbine—breast cancer	3.69e-05	0.000388	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Fluorouracil—breast cancer	3.67e-05	0.000387	CcSEcCtD
Regorafenib—Nausea—Melphalan—breast cancer	3.66e-05	0.000386	CcSEcCtD
Regorafenib—Malnutrition—Capecitabine—breast cancer	3.64e-05	0.000384	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—breast cancer	3.64e-05	0.000383	CcSEcCtD
Regorafenib—Pain—Fluorouracil—breast cancer	3.64e-05	0.000383	CcSEcCtD
Regorafenib—Gastrointestinal pain—Irinotecan—breast cancer	3.63e-05	0.000383	CcSEcCtD
Regorafenib—Gastrointestinal pain—Mitoxantrone—breast cancer	3.63e-05	0.000383	CcSEcCtD
Regorafenib—Infection—Paclitaxel—breast cancer	3.6e-05	0.000379	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—breast cancer	3.57e-05	0.000376	CcSEcCtD
Regorafenib—Nausea—Goserelin—breast cancer	3.57e-05	0.000376	CcSEcCtD
Regorafenib—Nervous system disorder—Paclitaxel—breast cancer	3.55e-05	0.000374	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—breast cancer	3.55e-05	0.000374	CcSEcCtD
Regorafenib—Thrombocytopenia—Paclitaxel—breast cancer	3.55e-05	0.000374	CcSEcCtD
Regorafenib—ABCB1—endocrine gland—breast cancer	3.53e-05	0.000662	CbGeAlD
Regorafenib—Diarrhoea—Thiotepa—breast cancer	3.52e-05	0.000371	CcSEcCtD
Regorafenib—Skin disorder—Paclitaxel—breast cancer	3.52e-05	0.000371	CcSEcCtD
Regorafenib—Abdominal pain—Mitoxantrone—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Body temperature increased—Irinotecan—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Abdominal pain—Irinotecan—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Body temperature increased—Mitoxantrone—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—breast cancer	3.51e-05	0.00037	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—breast cancer	3.48e-05	0.000366	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—breast cancer	3.47e-05	0.000365	CcSEcCtD
Regorafenib—Infestation—Methotrexate—breast cancer	3.47e-05	0.000365	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—breast cancer	3.44e-05	0.000362	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—breast cancer	3.44e-05	0.000362	CcSEcCtD
Regorafenib—Vomiting—Vinorelbine—breast cancer	3.43e-05	0.000361	CcSEcCtD
Regorafenib—Body temperature increased—Gemcitabine—breast cancer	3.42e-05	0.00036	CcSEcCtD
Regorafenib—Tremor—Capecitabine—breast cancer	3.41e-05	0.000359	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—breast cancer	3.41e-05	0.000359	CcSEcCtD
Regorafenib—Rash—Vinorelbine—breast cancer	3.4e-05	0.000358	CcSEcCtD
Regorafenib—Dermatitis—Vinorelbine—breast cancer	3.39e-05	0.000357	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—breast cancer	3.38e-05	0.000356	CcSEcCtD
Regorafenib—Headache—Vinorelbine—breast cancer	3.37e-05	0.000355	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—breast cancer	3.37e-05	0.000355	CcSEcCtD
Regorafenib—Anaemia—Capecitabine—breast cancer	3.37e-05	0.000355	CcSEcCtD
Regorafenib—Body temperature increased—Fluorouracil—breast cancer	3.36e-05	0.000354	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—breast cancer	3.3e-05	0.000347	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—breast cancer	3.28e-05	0.000346	CcSEcCtD
Regorafenib—Vomiting—Thiotepa—breast cancer	3.27e-05	0.000344	CcSEcCtD
Regorafenib—Leukopenia—Capecitabine—breast cancer	3.26e-05	0.000343	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—breast cancer	3.25e-05	0.000342	CcSEcCtD
Regorafenib—Infestation—Epirubicin—breast cancer	3.25e-05	0.000342	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—breast cancer	3.25e-05	0.000342	CcSEcCtD
Regorafenib—Rash—Thiotepa—breast cancer	3.24e-05	0.000342	CcSEcCtD
Regorafenib—Dermatitis—Thiotepa—breast cancer	3.24e-05	0.000341	CcSEcCtD
Regorafenib—Headache—Thiotepa—breast cancer	3.22e-05	0.000339	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—breast cancer	3.22e-05	0.000339	CcSEcCtD
Regorafenib—Nausea—Vinorelbine—breast cancer	3.2e-05	0.000337	CcSEcCtD
Regorafenib—Asthenia—Mitoxantrone—breast cancer	3.19e-05	0.000336	CcSEcCtD
Regorafenib—Asthenia—Irinotecan—breast cancer	3.19e-05	0.000336	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	3.18e-05	0.000335	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—breast cancer	3.17e-05	0.000333	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—breast cancer	3.15e-05	0.000332	CcSEcCtD
Regorafenib—Decreased appetite—Paclitaxel—breast cancer	3.15e-05	0.000332	CcSEcCtD
Regorafenib—Hypertension—Capecitabine—breast cancer	3.15e-05	0.000331	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—breast cancer	3.13e-05	0.00033	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—breast cancer	3.13e-05	0.00033	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Paclitaxel—breast cancer	3.13e-05	0.000329	CcSEcCtD
Regorafenib—Fatigue—Paclitaxel—breast cancer	3.12e-05	0.000329	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—breast cancer	3.12e-05	0.000328	CcSEcCtD
Regorafenib—Asthenia—Gemcitabine—breast cancer	3.11e-05	0.000327	CcSEcCtD
Regorafenib—Pain—Paclitaxel—breast cancer	3.1e-05	0.000326	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	3.08e-05	0.000324	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—breast cancer	3.08e-05	0.000324	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—breast cancer	3.07e-05	0.000323	CcSEcCtD
Regorafenib—Nausea—Thiotepa—breast cancer	3.06e-05	0.000322	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—breast cancer	3.05e-05	0.000322	CcSEcCtD
Regorafenib—Infection—Docetaxel—breast cancer	3.05e-05	0.000321	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—breast cancer	3.05e-05	0.000321	CcSEcCtD
Regorafenib—Diarrhoea—Irinotecan—breast cancer	3.04e-05	0.00032	CcSEcCtD
Regorafenib—Diarrhoea—Mitoxantrone—breast cancer	3.04e-05	0.00032	CcSEcCtD
Regorafenib—Dry mouth—Capecitabine—breast cancer	3.03e-05	0.000319	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—breast cancer	3.01e-05	0.000317	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—breast cancer	3.01e-05	0.000317	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—breast cancer	3.01e-05	0.000316	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—breast cancer	3.01e-05	0.000316	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—breast cancer	2.98e-05	0.000314	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—breast cancer	2.98e-05	0.000314	CcSEcCtD
Regorafenib—Gastrointestinal pain—Paclitaxel—breast cancer	2.96e-05	0.000312	CcSEcCtD
Regorafenib—Diarrhoea—Gemcitabine—breast cancer	2.96e-05	0.000312	CcSEcCtD
Regorafenib—Infection—Capecitabine—breast cancer	2.95e-05	0.000311	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—breast cancer	2.95e-05	0.00031	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—breast cancer	2.93e-05	0.000309	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—breast cancer	2.93e-05	0.000308	CcSEcCtD
Regorafenib—Nervous system disorder—Capecitabine—breast cancer	2.92e-05	0.000307	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—breast cancer	2.92e-05	0.000307	CcSEcCtD
Regorafenib—Diarrhoea—Fluorouracil—breast cancer	2.91e-05	0.000307	CcSEcCtD
Regorafenib—Thrombocytopenia—Capecitabine—breast cancer	2.91e-05	0.000307	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—breast cancer	2.89e-05	0.000304	CcSEcCtD
Regorafenib—Skin disorder—Capecitabine—breast cancer	2.89e-05	0.000304	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—breast cancer	2.88e-05	0.000303	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—breast cancer	2.87e-05	0.000302	CcSEcCtD
Regorafenib—Abdominal pain—Paclitaxel—breast cancer	2.86e-05	0.000302	CcSEcCtD
Regorafenib—Body temperature increased—Paclitaxel—breast cancer	2.86e-05	0.000302	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—breast cancer	2.86e-05	0.000301	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—breast cancer	2.84e-05	0.000299	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—breast cancer	2.83e-05	0.000298	CcSEcCtD
Regorafenib—Vomiting—Mitoxantrone—breast cancer	2.82e-05	0.000297	CcSEcCtD
Regorafenib—Vomiting—Irinotecan—breast cancer	2.82e-05	0.000297	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—breast cancer	2.81e-05	0.000296	CcSEcCtD
Regorafenib—Rash—Irinotecan—breast cancer	2.8e-05	0.000295	CcSEcCtD
Regorafenib—Rash—Mitoxantrone—breast cancer	2.8e-05	0.000295	CcSEcCtD
Regorafenib—Dermatitis—Mitoxantrone—breast cancer	2.8e-05	0.000295	CcSEcCtD
Regorafenib—Dermatitis—Irinotecan—breast cancer	2.8e-05	0.000295	CcSEcCtD
Regorafenib—Headache—Mitoxantrone—breast cancer	2.78e-05	0.000293	CcSEcCtD
Regorafenib—Headache—Irinotecan—breast cancer	2.78e-05	0.000293	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—breast cancer	2.76e-05	0.00029	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—breast cancer	2.75e-05	0.00029	CcSEcCtD
Regorafenib—Vomiting—Gemcitabine—breast cancer	2.75e-05	0.00029	CcSEcCtD
Regorafenib—Rash—Gemcitabine—breast cancer	2.73e-05	0.000287	CcSEcCtD
Regorafenib—Dermatitis—Gemcitabine—breast cancer	2.73e-05	0.000287	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—breast cancer	2.71e-05	0.000286	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—breast cancer	2.71e-05	0.000286	CcSEcCtD
Regorafenib—Headache—Gemcitabine—breast cancer	2.71e-05	0.000285	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—breast cancer	2.71e-05	0.000285	CcSEcCtD
Regorafenib—Vomiting—Fluorouracil—breast cancer	2.71e-05	0.000285	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—breast cancer	2.7e-05	0.000284	CcSEcCtD
Regorafenib—Rash—Fluorouracil—breast cancer	2.68e-05	0.000283	CcSEcCtD
Regorafenib—Dermatitis—Fluorouracil—breast cancer	2.68e-05	0.000282	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—breast cancer	2.67e-05	0.000281	CcSEcCtD
Regorafenib—Headache—Fluorouracil—breast cancer	2.67e-05	0.000281	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—breast cancer	2.66e-05	0.000281	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—breast cancer	2.65e-05	0.000279	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—breast cancer	2.65e-05	0.000279	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—breast cancer	2.65e-05	0.000279	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—breast cancer	2.65e-05	0.000279	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—breast cancer	2.64e-05	0.000278	CcSEcCtD
Regorafenib—Nausea—Mitoxantrone—breast cancer	2.64e-05	0.000278	CcSEcCtD
Regorafenib—Nausea—Irinotecan—breast cancer	2.64e-05	0.000278	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—breast cancer	2.63e-05	0.000277	CcSEcCtD
Regorafenib—Pain—Docetaxel—breast cancer	2.63e-05	0.000277	CcSEcCtD
Regorafenib—Asthenia—Paclitaxel—breast cancer	2.6e-05	0.000274	CcSEcCtD
Regorafenib—Decreased appetite—Capecitabine—breast cancer	2.58e-05	0.000272	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—breast cancer	2.58e-05	0.000271	CcSEcCtD
Regorafenib—Nausea—Gemcitabine—breast cancer	2.57e-05	0.000271	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Capecitabine—breast cancer	2.57e-05	0.00027	CcSEcCtD
Regorafenib—Fatigue—Capecitabine—breast cancer	2.56e-05	0.00027	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—breast cancer	2.55e-05	0.000269	CcSEcCtD
Regorafenib—Pain—Capecitabine—breast cancer	2.54e-05	0.000268	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—breast cancer	2.54e-05	0.000267	CcSEcCtD
Regorafenib—Nausea—Fluorouracil—breast cancer	2.53e-05	0.000266	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—breast cancer	2.51e-05	0.000264	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—breast cancer	2.51e-05	0.000264	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—breast cancer	2.5e-05	0.000264	CcSEcCtD
Regorafenib—Diarrhoea—Paclitaxel—breast cancer	2.48e-05	0.000261	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—breast cancer	2.45e-05	0.000258	CcSEcCtD
Regorafenib—ABCB1—lymph node—breast cancer	2.44e-05	0.000458	CbGeAlD
Regorafenib—Gastrointestinal pain—Capecitabine—breast cancer	2.43e-05	0.000256	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—breast cancer	2.43e-05	0.000256	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—breast cancer	2.43e-05	0.000256	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—breast cancer	2.43e-05	0.000256	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—breast cancer	2.43e-05	0.000256	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—breast cancer	2.38e-05	0.000251	CcSEcCtD
Regorafenib—Body temperature increased—Capecitabine—breast cancer	2.35e-05	0.000248	CcSEcCtD
Regorafenib—Abdominal pain—Capecitabine—breast cancer	2.35e-05	0.000248	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—breast cancer	2.35e-05	0.000247	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—breast cancer	2.35e-05	0.000247	CcSEcCtD
Regorafenib—Vomiting—Paclitaxel—breast cancer	2.3e-05	0.000243	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.29e-05	0.000241	CcSEcCtD
Regorafenib—Rash—Paclitaxel—breast cancer	2.28e-05	0.000241	CcSEcCtD
Regorafenib—Dermatitis—Paclitaxel—breast cancer	2.28e-05	0.00024	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—breast cancer	2.27e-05	0.000239	CcSEcCtD
Regorafenib—Headache—Paclitaxel—breast cancer	2.27e-05	0.000239	CcSEcCtD
Regorafenib—Asthenia—Docetaxel—breast cancer	2.2e-05	0.000232	CcSEcCtD
Regorafenib—Infection—Methotrexate—breast cancer	2.2e-05	0.000232	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—breast cancer	2.19e-05	0.000231	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—breast cancer	2.17e-05	0.000229	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—breast cancer	2.17e-05	0.000229	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—breast cancer	2.17e-05	0.000228	CcSEcCtD
Regorafenib—Nausea—Paclitaxel—breast cancer	2.15e-05	0.000227	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—breast cancer	2.15e-05	0.000226	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.15e-05	0.000226	CcSEcCtD
Regorafenib—Asthenia—Capecitabine—breast cancer	2.13e-05	0.000225	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—breast cancer	2.11e-05	0.000223	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—breast cancer	2.1e-05	0.000221	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—breast cancer	2.1e-05	0.000221	CcSEcCtD
Regorafenib—Infection—Epirubicin—breast cancer	2.06e-05	0.000217	CcSEcCtD
Regorafenib—Diarrhoea—Capecitabine—breast cancer	2.03e-05	0.000214	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—breast cancer	2.03e-05	0.000214	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—breast cancer	2.03e-05	0.000214	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—breast cancer	2.03e-05	0.000214	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—breast cancer	2.01e-05	0.000212	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.99e-05	0.000209	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—breast cancer	1.96e-05	0.000206	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—breast cancer	1.95e-05	0.000206	CcSEcCtD
Regorafenib—Rash—Docetaxel—breast cancer	1.94e-05	0.000204	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—breast cancer	1.93e-05	0.000204	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—breast cancer	1.92e-05	0.000203	CcSEcCtD
Regorafenib—Headache—Docetaxel—breast cancer	1.92e-05	0.000203	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—breast cancer	1.91e-05	0.000201	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—breast cancer	1.91e-05	0.000201	CcSEcCtD
Regorafenib—Infection—Doxorubicin—breast cancer	1.9e-05	0.000201	CcSEcCtD
Regorafenib—Pain—Methotrexate—breast cancer	1.89e-05	0.000199	CcSEcCtD
Regorafenib—Vomiting—Capecitabine—breast cancer	1.89e-05	0.000199	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—breast cancer	1.88e-05	0.000198	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—breast cancer	1.88e-05	0.000198	CcSEcCtD
Regorafenib—Rash—Capecitabine—breast cancer	1.87e-05	0.000197	CcSEcCtD
Regorafenib—Dermatitis—Capecitabine—breast cancer	1.87e-05	0.000197	CcSEcCtD
Regorafenib—Headache—Capecitabine—breast cancer	1.86e-05	0.000196	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—breast cancer	1.86e-05	0.000196	CcSEcCtD
Regorafenib—Nausea—Docetaxel—breast cancer	1.82e-05	0.000192	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—breast cancer	1.81e-05	0.000191	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—breast cancer	1.8e-05	0.00019	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—breast cancer	1.79e-05	0.000188	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—breast cancer	1.79e-05	0.000188	CcSEcCtD
Regorafenib—Pain—Epirubicin—breast cancer	1.77e-05	0.000187	CcSEcCtD
Regorafenib—Nausea—Capecitabine—breast cancer	1.77e-05	0.000186	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—breast cancer	1.75e-05	0.000184	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—breast cancer	1.75e-05	0.000184	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—breast cancer	1.69e-05	0.000178	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—breast cancer	1.67e-05	0.000175	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—breast cancer	1.65e-05	0.000174	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—breast cancer	1.65e-05	0.000174	CcSEcCtD
Regorafenib—Pain—Doxorubicin—breast cancer	1.64e-05	0.000173	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—breast cancer	1.64e-05	0.000172	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—breast cancer	1.64e-05	0.000172	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—breast cancer	1.59e-05	0.000167	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—breast cancer	1.57e-05	0.000165	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—breast cancer	1.52e-05	0.00016	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—breast cancer	1.52e-05	0.00016	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—breast cancer	1.51e-05	0.000159	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—breast cancer	1.49e-05	0.000157	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—breast cancer	1.42e-05	0.000149	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—breast cancer	1.41e-05	0.000148	CcSEcCtD
Regorafenib—Rash—Methotrexate—breast cancer	1.4e-05	0.000147	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—breast cancer	1.39e-05	0.000147	CcSEcCtD
Regorafenib—Headache—Methotrexate—breast cancer	1.39e-05	0.000146	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—breast cancer	1.38e-05	0.000145	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—breast cancer	1.32e-05	0.000139	CcSEcCtD
Regorafenib—Nausea—Methotrexate—breast cancer	1.31e-05	0.000138	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—breast cancer	1.31e-05	0.000138	CcSEcCtD
Regorafenib—Rash—Epirubicin—breast cancer	1.31e-05	0.000138	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—breast cancer	1.3e-05	0.000137	CcSEcCtD
Regorafenib—Headache—Epirubicin—breast cancer	1.3e-05	0.000137	CcSEcCtD
Regorafenib—Nausea—Epirubicin—breast cancer	1.23e-05	0.00013	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—breast cancer	1.22e-05	0.000128	CcSEcCtD
Regorafenib—Rash—Doxorubicin—breast cancer	1.21e-05	0.000127	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—breast cancer	1.21e-05	0.000127	CcSEcCtD
Regorafenib—Headache—Doxorubicin—breast cancer	1.2e-05	0.000126	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—breast cancer	1.14e-05	0.00012	CcSEcCtD
Regorafenib—ABCB1—Metabolism—NCOR1—breast cancer	3.71e-07	3.2e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—breast cancer	3.7e-07	3.19e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HPGDS—breast cancer	3.7e-07	3.19e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HBA1—breast cancer	3.68e-07	3.17e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—breast cancer	3.66e-07	3.16e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—breast cancer	3.66e-07	3.15e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—breast cancer	3.65e-07	3.15e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—breast cancer	3.65e-07	3.15e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GPX1—breast cancer	3.64e-07	3.14e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—breast cancer	3.64e-07	3.14e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—breast cancer	3.64e-07	3.14e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—breast cancer	3.64e-07	3.14e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—breast cancer	3.63e-07	3.13e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—breast cancer	3.63e-07	3.13e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—breast cancer	3.62e-07	3.13e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—breast cancer	3.61e-07	3.12e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1A1—breast cancer	3.6e-07	3.11e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—breast cancer	3.6e-07	3.11e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—breast cancer	3.6e-07	3.11e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—breast cancer	3.6e-07	3.11e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—breast cancer	3.6e-07	3.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—breast cancer	3.6e-07	3.1e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TGFB1—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ACHE—breast cancer	3.59e-07	3.1e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—breast cancer	3.58e-07	3.09e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—breast cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—breast cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—breast cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—breast cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—breast cancer	3.57e-07	3.08e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GPX1—breast cancer	3.55e-07	3.07e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK8—breast cancer	3.55e-07	3.06e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—breast cancer	3.55e-07	3.06e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—breast cancer	3.54e-07	3.05e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—breast cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TGFB1—breast cancer	3.53e-07	3.04e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—breast cancer	3.52e-07	3.04e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1A1—breast cancer	3.52e-07	3.03e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—breast cancer	3.51e-07	3.03e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—breast cancer	3.51e-07	3.03e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—breast cancer	3.51e-07	3.02e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—breast cancer	3.5e-07	3.02e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—breast cancer	3.49e-07	3.01e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAV1—breast cancer	3.47e-07	3e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLA2G4A—breast cancer	3.47e-07	2.99e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NCOR1—breast cancer	3.47e-07	2.99e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—breast cancer	3.47e-07	2.99e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—breast cancer	3.46e-07	2.98e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—breast cancer	3.45e-07	2.98e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—breast cancer	3.44e-07	2.97e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—breast cancer	3.44e-07	2.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—breast cancer	3.44e-07	2.97e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—breast cancer	3.43e-07	2.96e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—breast cancer	3.42e-07	2.95e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—breast cancer	3.42e-07	2.95e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP17A1—breast cancer	3.4e-07	2.93e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—breast cancer	3.38e-07	2.92e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—breast cancer	3.37e-07	2.91e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—breast cancer	3.37e-07	2.9e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO1—breast cancer	3.36e-07	2.9e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS1—breast cancer	3.36e-07	2.9e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—breast cancer	3.36e-07	2.9e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—breast cancer	3.36e-07	2.9e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—breast cancer	3.35e-07	2.89e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TGFB1—breast cancer	3.35e-07	2.89e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—breast cancer	3.35e-07	2.89e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—breast cancer	3.35e-07	2.89e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—breast cancer	3.34e-07	2.88e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TGFB1—breast cancer	3.34e-07	2.88e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—breast cancer	3.33e-07	2.87e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—breast cancer	3.33e-07	2.87e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—breast cancer	3.32e-07	2.87e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GPX1—breast cancer	3.32e-07	2.86e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—breast cancer	3.32e-07	2.86e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.32e-07	2.86e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—breast cancer	3.32e-07	2.86e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—breast cancer	3.3e-07	2.85e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2D6—breast cancer	3.3e-07	2.85e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1A1—breast cancer	3.29e-07	2.83e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—breast cancer	3.28e-07	2.83e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—breast cancer	3.28e-07	2.83e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—breast cancer	3.28e-07	2.83e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	3.28e-07	2.83e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—breast cancer	3.27e-07	2.82e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—breast cancer	3.27e-07	2.82e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—breast cancer	3.27e-07	2.82e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—breast cancer	3.26e-07	2.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—breast cancer	3.26e-07	2.81e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—breast cancer	3.25e-07	2.81e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—breast cancer	3.25e-07	2.8e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—breast cancer	3.24e-07	2.8e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—breast cancer	3.24e-07	2.8e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—breast cancer	3.24e-07	2.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOA2—breast cancer	3.24e-07	2.79e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—breast cancer	3.24e-07	2.79e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—breast cancer	3.24e-07	2.79e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—breast cancer	3.22e-07	2.78e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—breast cancer	3.19e-07	2.75e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK8—breast cancer	3.16e-07	2.73e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—breast cancer	3.16e-07	2.73e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—breast cancer	3.16e-07	2.73e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—breast cancer	3.16e-07	2.72e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—breast cancer	3.15e-07	2.72e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FASN—breast cancer	3.14e-07	2.71e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BCHE—breast cancer	3.13e-07	2.7e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—breast cancer	3.13e-07	2.7e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—breast cancer	3.1e-07	2.68e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—breast cancer	3.1e-07	2.67e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	3.1e-07	2.67e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAV1—breast cancer	3.1e-07	2.67e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—breast cancer	3.09e-07	2.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC5A5—breast cancer	3.09e-07	2.66e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—breast cancer	3.08e-07	2.66e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—breast cancer	3.06e-07	2.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—breast cancer	3.06e-07	2.64e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—breast cancer	3.05e-07	2.63e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAV1—breast cancer	3.03e-07	2.61e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—breast cancer	3.02e-07	2.6e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—breast cancer	3.02e-07	2.6e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	3.01e-07	2.6e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—breast cancer	3e-07	2.59e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—breast cancer	3e-07	2.59e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—breast cancer	2.99e-07	2.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NQO1—breast cancer	2.98e-07	2.57e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—breast cancer	2.98e-07	2.57e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.96e-07	2.55e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—breast cancer	2.96e-07	2.55e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—breast cancer	2.95e-07	2.54e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—breast cancer	2.95e-07	2.54e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—breast cancer	2.92e-07	2.52e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—breast cancer	2.92e-07	2.52e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—breast cancer	2.9e-07	2.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—breast cancer	2.89e-07	2.5e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—breast cancer	2.89e-07	2.49e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—breast cancer	2.88e-07	2.49e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—breast cancer	2.86e-07	2.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1B1—breast cancer	2.86e-07	2.47e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—breast cancer	2.85e-07	2.46e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	2.84e-07	2.45e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—breast cancer	2.84e-07	2.45e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—breast cancer	2.83e-07	2.44e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAV1—breast cancer	2.83e-07	2.44e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—breast cancer	2.82e-07	2.44e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—breast cancer	2.81e-07	2.42e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—breast cancer	2.81e-07	2.42e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.8e-07	2.42e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—breast cancer	2.79e-07	2.4e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—breast cancer	2.78e-07	2.4e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—breast cancer	2.78e-07	2.4e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—breast cancer	2.76e-07	2.38e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—breast cancer	2.76e-07	2.38e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—breast cancer	2.76e-07	2.38e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—breast cancer	2.75e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—breast cancer	2.74e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOA1—breast cancer	2.73e-07	2.35e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—breast cancer	2.72e-07	2.35e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—breast cancer	2.71e-07	2.34e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.7e-07	2.33e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—breast cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—STK11—breast cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP19A1—breast cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—breast cancer	2.69e-07	2.32e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TGFB1—breast cancer	2.68e-07	2.31e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—breast cancer	2.66e-07	2.3e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—breast cancer	2.66e-07	2.29e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—breast cancer	2.64e-07	2.27e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—breast cancer	2.63e-07	2.27e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—breast cancer	2.63e-07	2.27e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—breast cancer	2.63e-07	2.26e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—breast cancer	2.57e-07	2.22e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	2.56e-07	2.21e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—breast cancer	2.52e-07	2.18e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—breast cancer	2.52e-07	2.17e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—COMT—breast cancer	2.5e-07	2.16e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—breast cancer	2.5e-07	2.15e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—breast cancer	2.49e-07	2.15e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—breast cancer	2.48e-07	2.14e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—breast cancer	2.48e-07	2.14e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—breast cancer	2.48e-07	2.14e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—breast cancer	2.47e-07	2.13e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMOX1—breast cancer	2.45e-07	2.12e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—breast cancer	2.45e-07	2.12e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—breast cancer	2.45e-07	2.11e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ITPR1—breast cancer	2.45e-07	2.11e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—breast cancer	2.42e-07	2.09e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—breast cancer	2.42e-07	2.09e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—breast cancer	2.4e-07	2.07e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—breast cancer	2.39e-07	2.06e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—breast cancer	2.38e-07	2.05e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—breast cancer	2.37e-07	2.04e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—breast cancer	2.36e-07	2.03e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—breast cancer	2.34e-07	2.02e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—breast cancer	2.33e-07	2.01e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—breast cancer	2.32e-07	2e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—breast cancer	2.31e-07	2e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—breast cancer	2.29e-07	1.98e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—breast cancer	2.29e-07	1.98e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—breast cancer	2.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—breast cancer	2.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NCOR1—breast cancer	2.29e-07	1.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—breast cancer	2.28e-07	1.97e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—breast cancer	2.27e-07	1.96e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—breast cancer	2.26e-07	1.95e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—breast cancer	2.23e-07	1.93e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—breast cancer	2.21e-07	1.9e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GPX1—breast cancer	2.19e-07	1.89e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A1—breast cancer	2.17e-07	1.87e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—breast cancer	2.16e-07	1.87e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—breast cancer	2.15e-07	1.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—breast cancer	2.14e-07	1.85e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—breast cancer	2.14e-07	1.84e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—breast cancer	2.11e-07	1.82e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—breast cancer	2.11e-07	1.82e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—breast cancer	2.09e-07	1.81e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—breast cancer	2.09e-07	1.8e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—breast cancer	2.09e-07	1.8e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—breast cancer	2.02e-07	1.74e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—breast cancer	2.02e-07	1.74e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—breast cancer	1.97e-07	1.7e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—breast cancer	1.95e-07	1.69e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—breast cancer	1.94e-07	1.68e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—breast cancer	1.87e-07	1.61e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—breast cancer	1.86e-07	1.61e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAV1—breast cancer	1.86e-07	1.61e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—breast cancer	1.82e-07	1.57e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—breast cancer	1.75e-07	1.51e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—breast cancer	1.7e-07	1.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—breast cancer	1.7e-07	1.46e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—breast cancer	1.49e-07	1.29e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—breast cancer	1.48e-07	1.27e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—breast cancer	1.47e-07	1.27e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—breast cancer	1.43e-07	1.23e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—breast cancer	1.41e-07	1.22e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—breast cancer	1.32e-07	1.14e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.3e-07	1.12e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—breast cancer	1.29e-07	1.11e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—breast cancer	1.29e-07	1.11e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—breast cancer	1.21e-07	1.04e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—breast cancer	1.2e-07	1.04e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—breast cancer	1.12e-07	9.7e-07	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—breast cancer	1.08e-07	9.29e-07	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—breast cancer	1.05e-07	9.07e-07	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—breast cancer	9.82e-08	8.47e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—breast cancer	7.93e-08	6.84e-07	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—breast cancer	6.48e-08	5.59e-07	CbGpPWpGaD
